AWE Platform Strategy

Our AWE or Actinium Warhead Enabling Technology Platform utilizes the radioisotope Actinium-225, an alpha emitting isotope with distinct features making it the ideal payload. Actinium-225 is defined by its high linear energy of 5-8 MeV making it a potent payload capable of killing a cell with a single hit that is capable of causing double stranded breaks in a cell’s DNA. In the body, Actinium-225 travels a short distance measured in microns, which is the equivalent of only a few cells that limits damage to normal healthy cells and prevents wide-spread systemic toxicities. When linked to targeting agents such as antibodies, peptides, Fab fragments, nanobodies etc., Actinium-225’s energy can be used as effective payload for killing cancer cells.

Our AWE Technology Platform was co-developed with Memorial Sloan Kettering Cancer Center.  Our AWE Technology Platform is the basis for three of our drug candidates; Actimab-A that is being studied in a Phase 2 trial for patients with acute myeloid leukemia (AML), Actimab-M that is in a Phase 1 trial for patients with multiple myeloma and Actimab-MDS that is expected to begin a Phase 2 trial as a bridge to transplant for patients with myelodysplastic syndrome (MDS) that have a p53 genetic mutation.

We intend to develop a number of products for different types of cancer by implementing the following two strategies.

  • Monoclonal Antibody Expansion:  The strategy is to identify monoclonal antibodies (mAbs) with proven safety and robust cancer binding capabilities in unmet needs indications.
  • “Biobetters” Development:  With our AWE Technoloyg Platform, we can create second generation drugs with superior efficacy for marketed mAb drugs.  As patent protection for many native mAbs approaches expiration, we will be able to offer the owners of those mAbs our technology that will create new, better drugs and give them new patent protection.  We intend to form valuable alliances, joint ventures and/or licensing deals with companies having commercial mAb drugs.  We expect this strategy to result in additional growth potential for the company